David Hoang
Stock Analyst at Deutsche Bank
(3.15)
# 1,226
Out of 5,091 analysts
47
Total ratings
48.65%
Success rate
2.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.40 | +53.06% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $271.25 | +3.23% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $34.64 | +24.13% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $38.92 | -7.50% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $21.92 | -45.26% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $26.70 | +31.09% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $44.54 | +50.43% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $19.67 | +57.60% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $10.54 | +516.70% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $148.40 | +18.60% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.31 | -43.69% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $154.92 | +1.99% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.93 | +262.69% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.72 | +179.72% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.33 | +269.52% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $429.24 | -48.75% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $68.65 | +16.54% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.43 | -12.54% | 1 | Dec 7, 2022 |
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.40
Upside: +53.06%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $271.25
Upside: +3.23%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $34.64
Upside: +24.13%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $38.92
Upside: -7.50%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $21.92
Upside: -45.26%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $26.70
Upside: +31.09%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $44.54
Upside: +50.43%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $19.67
Upside: +57.60%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $10.54
Upside: +516.70%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $148.40
Upside: +18.60%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $21.31
Upside: -43.69%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $154.92
Upside: +1.99%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.93
Upside: +262.69%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.72
Upside: +179.72%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.33
Upside: +269.52%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $429.24
Upside: -48.75%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $68.65
Upside: +16.54%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $3.43
Upside: -12.54%